HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tamura, M. Articles by Kashmiri, S. V. S. Search for Related Content PubMed PubMed Citation Articles by Tamura, M. Articles by Kashmiri, S. V. S.

Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only

Midori Tamura^1,*, Diane E. Milenic^*, Makoto Iwahashi^2,*, Eduardo Padlan, Jeffrey Schlom^3,* and S. V. S. Kashmiri^*

^* Laboratory of Tumor Immunology and Biology, National Cancer Institute, and Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892

Clinical utility of murine mAbs is limited because many elicit Abs to murine Ig constant and variable regions in patients. An Ab humanized by the current procedure of grafting all the complementarity determining regions (CDRs) of a murine Ab onto the human Ab frameworks is likely to be less immunogenic, except that its murine CDRs could still evoke an anti-variable region response. Previous studies with anticarcinoma mAb CC49 showed that light chain LCDR1 and LCDR2 of humanized CC49 could be replaced with the corresponding CDRs of a human Ab with minimal loss of Ag-binding activity. The studies reported in this paper were undertaken to dissect the CC49 Ag-binding site to identify 1) specificity determining residues (SDRs), the residues of the hypervariable region that are most critical in Ag-Ab interaction, and 2) those residues that contribute to the idiotopes that are potential targets of patients’ immune responses. A panel of variants generated by genetic manipulation of the murine CC49 hypervariable regions were evaluated for their relative Ag-binding affinity and reactivity to sera from several patients who had been immunized with murine CC49. One variant, designated HuCC49V10, retained only the SDRs of CC49 and does not react with the anti-variable region Abs of the sera from the murine CC49-treated patients. These studies thus demonstrate that the genetic manipulation of Ab variable regions can be accomplished by grafting only the SDRs of a xenogeneic Ab onto human Ab frameworks. This approach may reduce the immunogenicity of Abs to a minimum.

This article has been cited by other articles:

				R. De Pascalis, N. R. Gonzales, E. A. Padlan, P. Schuck, S. K. Batra, J. Schlom, and S. V. S. Kashmiri In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants Clin. Cancer Res., November 15, 2003; 9(15): 5521 - 5531. [Abstract] [Full Text] [PDF]

				R. De Pascalis, M. Iwahashi, M. Tamura, E. A. Padlan, N. R. Gonzales, A. D. Santos, M. Giuliano, P. Schuck, J. Schlom, and S. V. S. Kashmiri Grafting of "Abbreviated" Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody J. Immunol., September 15, 2002; 169(6): 3076 - 3084. [Abstract] [Full Text] [PDF]

				S. V.S. Kashmiri Multivalent Single-Chain Antibodies for Radioimaging of Tumors J. Nucl. Med., October 1, 2001; 42(10): 1528 - 1529. [Full Text] [PDF]

				D. L. Meyer, J. Schultz, Y. Lin, A. Henry, J. Sanderson, J. M. Jackson, S. Goshorn, A. R. Rees, and S. S. Graves Reduced antibody response to streptavidin through site-directed mutagenesis Protein Sci., March 1, 2001; 10(3): 491 - 503. [Abstract] [Full Text]